Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Resources

Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Sector: Diagnostics
Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan dive into the FDA’s new regulations surrounding Laboratory Developed Tests (LDTs) and their impact on the medical device industry. As LDTs grow in complexity, including applications like genetic testing and AI-driven diagnostics, these regulatory changes mark a significant shift for laboratories, developers, and healthcare providers.

Nick, drawing on his experience with medical device development, explains the critical distinctions between LDTs and In Vitro Diagnostics (IVDs). He provides insights into why these changes are happening and what they mean for developers working to bring innovative diagnostic tools to market.

Key takeaways from the episode include:

  • Understanding the Difference: LDTs are clinically validated tests performed in CLIA-approved labs but do not require FDA regulatory clearance, unlike IVDs, which are classified as medical devices.
  • The Shift in Regulation: The FDA is transitioning from selective enforcement to increased scrutiny due to the growing complexity and impact of LDTs, such as cancer diagnostics and genetic testing.
  • Implications for Developers: Nick explores how the new regulations add layers of oversight but also improve the safety, accuracy, and reliability of tests with far-reaching implications for patient care.

Joris and Nick discuss the broader industry impacts, including the challenges and opportunities presented by these regulatory changes. While some pushback is expected, they highlight how these steps are ultimately beneficial for innovation and patient outcomes, ensuring that advanced diagnostics meet higher standards of clinical utility and reliability.

This episode is essential viewing for medical device developers, diagnostic innovators, and healthcare professionals navigating the evolving regulatory landscape. Gain a clear understanding of how the FDA’s increased involvement in LDTs is shaping the future of diagnostics and how to stay ahead in this rapidly changing environment.

Laboratory Developed Tests vs. In Vitro Diagnostics

YouTube video thumbnail

Read our article on the impact of FDA Laboratory Developed Tests 2024 Policy update to its regulatory approach for in vitro diagnostic products (IVDs), including laboratory developed tests (LDTs). 

Team reviewing market data and planning a MedTech commercialization strategy around a table.

Are You Developing a Product or a Company?

Every MedTech startup begins with a hypothesis, an idea that could transform patient outcomes, simplify delivery of care, or improve how clinicians diagnose and treat patients.

Close up of a dishwasher spray bar opened to reveal hidden internal gears, highlighted with a red arrow and the text “Hidden Tech.”

Dishwasher Engineering Insights for Device Reprocessing

When Ariana Wilson and Mark Drlik take apart a common appliance, they uncover engineering principles that connect directly to medtech.

Nick showing a biofilm conference book while Nigel listens, with overlay text reading FDA Asked For It and a red arrow pointing to the book.

Biofilm Referencing Lesson

When reviewing evidence for a medical device, a single citation can shape an entire submission. In this Bio Break episode, Nick shares a biofilm referencing lesson that has stayed with him since the early 2000s.

Diagram showing medical device at the center connected to clinicians, patients, and regulatory bodies with text 'Who are we designing for?' highlighting stakeholder mapping in MedTech design.

Understanding Medical Device Stakeholders

Every phase of a device’s life cycle involves different people with distinct needs—from clinicians and patients to service technicians and regulatory bodies.